Model is a hypothetical patient profile, for illustrative purposes only
*Data from ASTERIA II; two other phase III studies (ASTERIA I and GLACIAL) were also conducted to assess efficacy and safety of Xolair® in inadequately controlled CSU patients
**Xolair® is also available as a lyophilized formulation
†Xolair® 300mg vs. baseline at 12 weeks; p<0.001 vs placebo. DLQI: Dermatology Life Quality Index.
‡From weeks 4—12 with Xolair® 300 mg vs. placebo (89.2%); p<0.001.
References: 1. Maurer M, et al. N Engl J Med 2013;368:924-935. 2. Casale T, et al. Allergy 2014;69(Suppl 99). Abstr 1662. 3. Xolair® Summary of Product Characteristics 2016